Anti-Tau Monoclonal Antibody Therapies represent a promising disease-modifying approach for Alzheimer's disease and other tauopathies. These monoclonal antibodies target pathological tau protein aggregates, aiming to slow or halt disease progression by clearing toxic tau species from the brain[1].
Anti-tau monoclonal antibodies (mAbs) represent the most advanced disease-modifying approach for tauopathies beyond symptomatic treatments. Unlike kinase inhibitors or aggregation inhibitors, these antibodies directly target pathological tau species and facilitate their clearance through the brain's innate immune system. The field has evolved through multiple generations of antibody engineering, from N-terminal targeting approaches to more sophisticated microtubule-binding region (MTBR) and phosphorylated tau (p-tau) targeting strategies.
The clinical development landscape has been marked by significant challenges—most anti-tau antibodies have failed to meet primary clinical endpoints despite showing biomarker effects. This disconnect between biomarker engagement and clinical efficacy remains a central puzzle in the field. However, newer antibodies targeting the MTBR show more promise, and combination approaches with anti-amyloid antibodies are being explored.
Pathological tau forms neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau oligomers and fibrils. Anti-tau immunotherapies work through multiple mechanisms[2]:
| Drug Name | Company | Target Epitope | Stage | Indication | Key Results |
|---|---|---|---|---|---|
| Semorinemab (RO7105705) | Genentech/Roche | Mid-domain (aa 6-23) | Phase 2 | AD, PSP | Mixed: reduced CSF tau, no cognitive benefit in AD; slowed PSP progression |
| Zagotenemab (BE19071) | Eli Lilly | Conformational p-tau | Phase 2 | AD | Biomarker effects but missed primary endpoint in TRAILBLAZER-ALZ 2 |
| Bepranemab (UCB0107) | UCB | Mid-domain (aa 235-246) | Phase 2 | AD, PSP | Phase 2a TOGETHER: biomarker reduction; subgroup benefit in low-tau, non-APOE4 |
| Tilavonemab (ABBV-8E12) | AbbVie | N-terminal tau | Phase 2 (discontinued) | AD, PSP | Did not meet primary endpoints in both indications |
| Gosuranemab (BIIB092) | Biogen | N-terminal fragments | Phase 2 (discontinued) | AD, TBI | Discontinued after Phase 2 failure |
| JNJ-63733657 (Posdinemab) | Johnson & Johnson | p-tau217 | Phase 2 | AD | Phase 1: significant CSF p-tau217 reduction; Phase 2 data expected |
| Lu AF87908 | Lundbeck | Phospho-tau | Phase 1 | AD | Completed Phase 1 (July 2023); further development unclear |
| PNT001 | Pinteon Therapeutics | cis-p-tau | Phase 1/2 | AD, TBI | Targets pathological cis-p-tau conformation |
| E2814 (Etalanetug) | Eisai | MTBR-tau | Phase 2/3 | DIAD | DIAN-TU NexGen: -75% CSF MTBR-tau243 at 9 months; promising combo with lecanemab |
Developed by Genentech/Roche, semorinemab targets the mid-domain of tau (amino acids 6-23)[3].
Developed by Eli Lilly, zagotenemab targets conformational phosphorylated tau epitopes[4].
Developed by UCB, bepranemab targets the mid-domain of tau (residues 235-246)[5].
Developed by AbbVie, tilavonemab targets N-terminal tau[6].
Developed by Biogen, gosuranemab targets N-terminal tau fragments[7].
Developed by Johnson & Johnson, posdinemab targets phosphorylated tau at the p-tau217 epitope[8].
Developed by Lundbeck, Lu AF87908 is an anti-phospho-tau antibody[9].
Developed by Pinteon Therapeutics, PNT001 targets cis-p-tau[10].
Developed by Eisai, E2814 is a human IgG1 antibody targeting the MTBR-tau[11].
| Rank | Antibody | Evidence Level | Key Differentiator |
|---|---|---|---|
| 1 | E2814 | High | Direct MTBR targeting, strongest biomarker data (-75% MTBR-tau), no ARIA |
| 2 | Bepranemab | Moderate-High | Mid-domain targeting, clear biomarker effects, subgroup efficacy signal |
| 3 | Semorinemab | Moderate | PSP benefit, biomarker reductions in AD |
| 4 | JNJ-63733657 | Moderate | Strong Phase 1 target engagement, Phase 2 pending |
| 5 | Zagotenemab | Moderate | Biomarker effects in TRAILBLAZER-ALZ 2 |
| 6 | PNT001 | Low-Moderate | Novel cis-p-tau target, early-stage |
| 7 | Lu AF87908 | Low | Phase 1 complete, unclear path forward |
| 8-9 | Gosuranemab/Tilavonemab | Low | Discontinued—failed Phase 2 |
| Disease | Rationale | Antibodies Studied | Status |
|---|---|---|---|
| Alzheimer's Disease | Tau pathology correlates with cognitive decline | All 9 candidates | Multiple trials in Phase 2/3 |
| Progressive Supranuclear Palsy | Primary 4R tauopathy | Semorinemab, Bepranemab, Tilavonemab, Gosuranemab | Mixed results |
| Corticobasal Degeneration | 4R tauopathy | Tilavonemab | Early-stage trials |
| Traumatic Brain Injury | tau pathology | PNT001, Gosuranemab | Early-stage |
| Dominantly Inherited AD | Genetic AD | E2814 | DIAN-TU NexGen |
| Antibody | ARIA-E | ARIA-H | Key Safety Notes |
|---|---|---|---|
| Anti-tau mAbs (general) | 2-5% | <5% | Much lower than anti-amyloid |
| E2814 | 0% | 0% | No ARIA signal reported |
| Semorinemab | Low | Low | Generally well-tolerated |
| Bepranemab | Low | Low | Acceptable safety profile |
| Vaccine | Company | Target | Stage | Notes |
|---|---|---|---|---|
| AADvac1 | Axon Neuroscience | p-tau (Thr181) | Phase 2 | Showed safety and immunological response |
| ACI-35 | AC Immune | p-tau (Ser396/404) | Phase 1b/2a | Liposome-based vaccine |
Danysz W, et al. Tau Immunotherapy: Progress and Challenges. Alzheimer's Dementia. 2023. ↩︎
Lee SH, et al. Anti-tau Antibody Mechanisms. J Clin Invest. 2024. ↩︎
Galloni C, et al. Semorinemab CITADEL Studies. Alzheimer's Res Ther. 2023. ↩︎
Teng E, et al. Zagotenemab in Early Alzheimer's Disease. JAMA Neurol. 2024. ↩︎
UCB. Bepranemab Phase 2a Study Results at CTAD 2024. 2024. ↩︎
Boxer AL, et al. Tilavonemab in Progressive Supranuclear Palsy. Neurology. 2021. ↩︎
Qureshi M, et al. Gosuranemab in Alzheimer's Disease. Alzheimer's Res Ther. 2022. ↩︎
Johnson & Johnson. JNJ-63733657 Phase 1 Results. Clinical Development Pipeline. ↩︎
Lundbeck. Lu AF87908 Phase 1 Completion. Press Release. 2023. ↩︎
Pinteon Therapeutics. PNT001 Development. Corporate Information. ↩︎
E2814 DIAN-TU Study. ALZFORUM Therapeutics Database. ↩︎